The article compares the use of epicutaneous immunotherapy and placebo in the management of peanut protein ingestion among children with peanut allergy. It highlights the advantages of epicutaneous immunotherapy, including ease of use and a lower risk of allergic reactions. Also presented are recommendations from the U.S. Food and Drug Administration (FDA) on the use of both approaches.